Fairman Group’s Prime Medicine PRME Stock Holding History

Fairman Group’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.53K	Hold	500	–	–	﹤0.01%	289
2026 Q2	$1.84K	Hold	500	–	–	﹤0.01%	289
2026 Q1	$1.74K	Hold	500	–	–	﹤0.01%	285
2025 Q4	$1.74K	Hold	500	–	–	﹤0.01%	293
2025 Q3	$2.77K	Hold	500	–	–	﹤0.01%	219
2025 Q2	$1.24K	Hold	500	–	–	﹤0.01%	218
2025 Q1	$1.46K	Hold	500	–	–	﹤0.01%	210
2024 Q4	$1.46K	Hold	500	–	–	﹤0.01%	239
2024 Q3	$1.94K	Hold	500	–	–	﹤0.01%	279
2024 Q2	$2.57K	Hold	500	–	–	﹤0.01%	246
2024 Q1	$3.5K	Hold	500	–	–	﹤0.01%	213
2023 Q4	$4.43K	Buy	+500	New	+$3.85K	﹤0.01%	200

Other funds holding PRME

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.95% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Fairman Group's PRME Position: Q3 2026 in Review

Fairman Group held its Prime Medicine (PRME) position steady in Q3 2026 at 500 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

Fairman Group first reported a position in PRME in Q4 2023 and has held it in 12 quarters since. The position peaked at $4.43K in Q4 2023. 46 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Fairman Group held 500 shares of Prime Medicine worth $1.53K as of Q3 2026.
Fairman Group left its Prime Medicine share count unchanged in Q3 2026.
Prime Medicine made up ﹤0.01% of Fairman Group's portfolio in Q3 2026, its #289 holding.
Fairman Group first reported a position in Prime Medicine in Q4 2023 and has held it in 12 quarters since.
Fairman Group's Prime Medicine position peaked at $4.43K in Q4 2023.
46 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.